Key terms
About CRIS
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest CRIS news
Mar 25
8:31am ET
Two new option listings and option delistings on March 25th
Mar 08
7:15am ET
Curis (CRIS) Gets a Buy from Truist Financial
Feb 26
11:45am ET
Truist biotech analysts hold an analyst/industry conference call
Feb 26
4:55am ET
Truist biotech analysts hold an analyst/industry conference call
Feb 21
12:10pm ET
Truist biotech analysts hold an analyst/industry conference call
Feb 10
1:00am ET
Curis Inc. Is Worried About This – Should You Be Worried Too?
Feb 09
8:10am ET
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS) and Curis (CRIS)
Feb 09
6:20am ET
Analysts Are Bullish on Top Healthcare Stocks: Foghorn Therapeutics (FHTX), Sensus Healthcare (SRTS)
Feb 09
6:12am ET
Curis price target lowered to $26 from $51 at H.C. Wainwright
Feb 08
4:29pm ET
Curis files $300M common stock offering
Feb 08
8:08am ET
Curis sees cash, cash equivalents and investments sufficient into 2025
Feb 08
8:08am ET
Curis reports Q4 EPS ($2.03), consensus ($2.11)
No recent press releases are available for CRIS
CRIS Financials
Key terms
Ad Feedback
CRIS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
CRIS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range